Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer
-
- STATUS
- Recruiting
-
- End date
- May 9, 2025
-
- participants needed
- 20
-
- sponsor
- M.D. Anderson Cancer Center
Summary
This phase I trial investigates the side effects and effectiveness of chemotherapy followed by a donor (allogeneic) stem cell transplant when given to patients with high grade brain cancer. Chemotherapy drugs, such as fludarabine, thiotepa, etoposide, melphalan, and rabbit anti-thymocyte globulin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before a donor stem cell transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. When the healthy stem cells from a donor are infused into a patient, they may help the patient's bone marrow make more healthy cells and platelets and may help destroy any remaining cancer cells.
Description
PRIMARY OBJECTIVE:
I. To assess tolerability of allogenic hematopoietic cell transplantation (HCT) among patients with chemo-responsive high-grade central nervous system (CNS) malignancies as defined by transplant-related mortality (TRM) at day 30 as well as rate of grade III organ toxicity or higher (Bearman Regimen-Related Toxicities Scale) attributable to conditioning occurring within 30 days.
SECONDARY OBJECTIVES:
I. Median time to platelet and neutrophil engraftment. II. Incidence of acute graft-versus-host disease (aGVHD) by day 100. III. Incidence of chronic GVHD at day 100 and one year. IV. Rate of grade II organ toxicity through day 100. V. Rate of graft failure (primary and secondary) through day 100. VI. Rate of infectious complications through day 100. VII. Progression free survival at day 180. VIII. Cumulative incidence of relapse, overall survival, and progression-free survival at 100 days and 1 year.
- OUTLINE
Patients receive thiotepa intravenously (IV) over 2-4 hours and etoposide IV over 60 minutes on days -8 to -6, melphalan IV over 20 minutes on days -5 and -4, and fludarabine phosphate IV over 1 hour on days -5 to -3. Patients receiving umbilical cord transplant only also receive lapine T-lymphocyte immune globulin IV over 4-12 hours on days -4 and -3. Patients then undergo HCT on day 0. Patients also receive tacrolimus IV or cyclosporine IV beginning on day -2 to and mycophenolate mofetil orally (PO) every 8 hours or IV from days 0-40 and tapered to day 90.
After completion of study treatment, patients are followed up at 100, 180, 270 and 360 days.
Details
| Condition | Ependymoma, Medulloblastoma, Neuroectodermal Tumor, Neurectoderma, Glioma, Gliomas, Primitive neuroectodermal tumor, Malignant neoplasm of brain, Brain Cancer, Brain Tumor, Brain Tumor (Pediatric), Brain Tumor (Pediatric), Recurrent Malignant Glioma, High Grade Glioma, Atypical Teratoid/Rhabdoid Tumor, Atypical Teratoid Rhabdoid Tumor, Choroid Plexus Carcinoma, Neurectoderma, Recurrent Medulloblastoma, Recurrent Primitive Neuroectodermal Tumor, Brain Cancer, Gliomas, Brain Tumor, Recurrent Malignant Brain Neoplasm, malignant glioma, primitive neuroectodermal tumour, pnet, malignant brain tumor, Central Nervous System Germ Cell Tumor, Intracranial Myeloid Sarcoma, Recurrent Anaplastic Ependymoma, Recurrent Atypical Teratoid/Rhabdoid Tumor, Recurrent Atypical Teratoid/Rhabdoid Tumor, Recurrent Atypical Teratoid/Rhabdoid Tumor, Recurrent Atypical Teratoid/Rhabdoid Tumor |
|---|---|
| Treatment | fludarabine phosphate, mycophenolate mofetil, etoposide, melphalan, Tacrolimus, Hematopoietic Cell Transplantation, thiotepa, Lapine T-Lymphocyte Immune Globulin |
| Clinical Study Identifier | NCT04521946 |
| Sponsor | M.D. Anderson Cancer Center |
| Last Modified on | 2 March 2021 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer